Table 3

Logistic regression analysis of risk of all-grade dermatological and endocrine toxicity in patients receiving immune checkpoint inhibitors

	Dermatological toxicity		Endocrine toxicity
	Univariate	Multivariable	Univariate	Multivariable
Age category
<65 years	1.00 (ref)	1.00 (ref)	1.00 (ref)	1.00 (ref)
65–74 years	1.21 (0.71 to 2.05)	1.34 (0.77 to 2.30)	0.93 (0.55 to 1.56)	1.08 (0.63 to 1.83)
≥75 years	1.69 (0.97 to 2.95)	1.85 (1.04 to 3.30)	0.42 (0.21 to 0.84)	0.43 (0.21 to 0.87)
Primary site
Melanoma	1.00 (ref)	1.00 (ref)	1.00 (ref)	1.00 (ref)
NSCLC	0.62 (0.35 to 1.08)	0.69 (0.39 to 1.23)	0.47 (0.24 to 0.89)	0.42 (0.21 to 0.82)
RCC	0.75 (0.40 to 1.41)	0.95 (0.49 to 1.86)	1.28 (0.70 to 2.33)	1.16 (0.61 to 2.18)
Treatment type
PD-1 inhibitor	1.00 (ref)	1.00 (ref)	1.00 (ref)	1.00 (ref)
Ipilimumab+nivolumab	2.56 (1.01 to 6.49)	2.46 (0.94 to 6.46)	1.07 (0.35 to 3.29)	0.89 (0.28 to 2.85)
Ipilimumab	1.48 (0.78 to 2.8)	1.61 (0.81 to 3.19)	1.22 (0.61 to 2.44)	1.00 (0.48 to 2.09)

OR by logistic regression for all-grade dermatological and endocrine toxicity (95% CIs).
NSCLC, non-small cell lung cancer; RCC, renal cell carcinoma.